English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Glioblastoma is the most common and most lethal of all primary brain tumors. Even with the standard triad of surgery, chemotherapy, and radiation therapy, life expectancy is still poor, with a median survival less than 15 months following initial diagnosis. Even though the extent of surgical resection is a prognostic factor affecting outcome, most surgical studies have noted that the complete resection rates are poor due to difficulty in defining the tumor margin intraoperatively. Fluorescence-guided resection (FGR) helps to visualize tumor cells, allowing more complete resection. 5-aminolevulinic acid (5-ALA) in glioma resection has been widely used around the world; however, it is has not been approved in the United States. In this paper, we report two cases of long-term progression-free survival in patients with glioblastoma surgically resected using of 5-ALA.

The Use of 5-ALA in Glioblastoma Resection: Two Cases with Long-Term Progression-Free Survival